UNSPSC 51373336: Buprenorphine/naloxone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373336 Buprenorphine/naloxone is a Commodity code that covers opioid-use-disorder medications and related overdose-reversal products. State and local governments procure naloxone and buprenorphine/naloxone formulations for community health programs, emergency response, and public health initiatives, typically through competitive bidding. The work involves purchasing finished pharmaceutical products and related systems—such as naloxone auto-injectors or safe drug deactivation systems—for distribution through county health departments, community health centers, and emergency services. Issuing bodies include county health departments and municipal public health agencies that manage overdose prevention and substance-use treatment programs.

Recent activity shows Seminole County, Florida soliciting naloxone and safe drug deactivation systems through an IFB (Invitation for Bid) posted June 30, 2026, with a response deadline of July 26, 2023. The solicitation called for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. Bidders were required to include all shipping and delivery costs in their proposals, provide unit costs per line item, comply with E-Verify requirements and drug-free workplace certification, and carry workers' compensation and commercial general liability coverage. The contract included an initial two-year term with a one-year renewal option and a three-month probationary period; procurement potentially involved FEMA funding and related federal compliance obligations. The source contains no other recent state or local opportunities under this code.